$5.81−0.39 (−6.29%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Candel Therapeutics (CADL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend (through FY22), net margin −15035.2%. Worth your attention in FY25: Share count (+180.6%) and Capex step-up ($587.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲30.8%
−38.2
FY21→FY25CAGR —
Free cash flow ($M)▼43.9%
−38.9
capex stepped upCAGR —
Diluted EPS▲58.6%
−0.72
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+180.6%
18.9mn → 53.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$587.0K
▲3569% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6843, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 125.0 | 125.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 125.0 | 125.0 | — | — |
Research & development | 56,256.0 | 30,496.0 | 19,314.0 | 24,506.0 | 20,787.0 | 15,178.0 | ▲57.9% | +19.1% |
Selling, general & admin | 25,507.0 | 17,770.0 | 14,057.0 | 13,885.0 | 14,060.0 | 10,673.0 | ▲26.4% | +13.6% |
Total operating expenses | 81,763.0 | 48,266.0 | 33,371.0 | 38,391.0 | 34,847.0 | 25,851.0 | ▲44.6% | +16.9% |
Operating incomefeeds ROC rank | −81,763.0 | −48,266.0 | −33,371.0 | −38,391.0 | −34,722.0 | −25,726.0 | ▼44.6% | — |
Other income, net | −17,372.0 | 10,084.0 | −21,806.0 | 452.0 | 15,928.0 | −10,398.0 | — | — |
Pretax income | −99,135.0 | −38,182.0 | −55,177.0 | −37,939.0 | −18,794.0 | −36,124.0 | ▲30.8% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −99,135.0 | −38,182.0 | −55,177.0 | −37,939.0 | −18,794.0 | −36,124.0 | ▲30.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.49 | −0.72 | −1.74 | −1.31 | −0.65 | −1.91 | ▲58.6% | — |
Diluted shares (mn) | 77.39 | 52.96 | 31.68 | 28.94 | 28.82 | 18.87 | ▲67.2% | +29.4% |
| Margins | ||||||||
Gross margin | — | — | — | — | 100.0% | 100.0% | — | — |
Operating margin | — | — | — | — | −27777.6% | −20580.8% | — | — |
Net margin2nd pct in Healthcare | — | — | — | — | −15035.2% | −28899.2% | — | — |
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

